Showing 671-680 of 1100 results for "".
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- Ortho Dermatologics Names 2022 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2022-aspire-higher-scholarship-recipients/2461356/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently named the recipients of their 2022 Aspire Higher Scholarship program. The program, which has provided a total of $918,000 in scholarships since launching in 2013, will award nine students who have been treate
- A New Look for Merz Aestheticshttps://practicaldermatology.com/news/a-new-look-for-merz-aesthetics/2461352/Merz Aesthetics has launched a new corporate visual identity to underscore the company's commitment to putting the definition of beauty back into the hands of the individual through a vibrant and distinct color palette along with strong and joyful photography. The new visual identit
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- Online Extra: Let’s Talk About Truncal Acnehttps://practicaldermatology.com/news/online-extra-lets-talk-about-truncal-acne/2461304/While often trivialized as a cosmetic skin disease, acne is in fact an inflammatory skin condition with a complex pathogenesis associated with a significant physical and psychological burden. Approximately 50% of people with facial acne also have truncal acne manifesting on the back, shoulders, a
- Researchers Discover New Approach to Healing Skin Infections, Woundshttps://practicaldermatology.com/news/researchers-discover-new-approach-to-healing-skin-infections-wounds/2461302/New research may lead to advancements in treating bacterial infections and wounds. Monocytes alone are capable of facilitating faster healing of wounds. Monocytes help the healing process by regulating leptin levels and blood vessel growth during wound repair. They also produce ghrelin,
- Dial Joins Forces with DonorsChoose and TeacherLists to Support Teachershttps://practicaldermatology.com/news/dial-joins-forces-with-donorschoose-and-teacherlists-to-supoort-teachers/2461264/Dial is doubling down on efforts to support teachers with a back-to-school marketing campaign. For the second year in a row, Dial has partnered with
- Systemic Inhibition of S100A9 May Reduce Severity of PsO, PsAhttps://practicaldermatology.com/news/systemic-inhibition-of-s100a9-may-reduce-severity-of-pso-psa/2461262/The severity of psoriasis and psoriatic arthritis can be reduced by inhibiting S100A9 systemically throughout the whole body rather than locally on the skin, according to a new study. By way of background, S100A9 activation in skin and immune cells has been identified as a risk factor f
- Business News: Solta IPO Put on Icehttps://practicaldermatology.com/news/business-news-solta-ipo-put-on-ice/2461239/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a